Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Syros Pharmaceuticals Implements Genedata Profiler to Accelerate Therapeutic Development for Genomically Targeted Patient Populations

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, announced that Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, has chosen Genedata Profiler as its data integration and analytics platform to accelerate its translational research strategy.

While much of target discovery has focused on inhibiting or changing the function of abnormal genes and proteins, Syros’ unique ability to elucidate regulatory regions of the genome allows to home in on which genes to control, in which cells, and for which patients to best modulate their expression. Such an approach has a potential to maximize the efficacity of treatment and provide a profound benefit for previously unserved patients.

Recommended AI News: Microsoft Industry Cloud Could Be a Worthwhile Consideration, According to Info-Tech Research Group

Under the terms of the agreement, Syros is licensing Genedata Profiler to speed up the development of such targeted medicines. As part of the deal, Genedata also is committing consulting resources to digitalize processes specific to Syros Pharmaceuticals.

“To accelerate the development of medicines for genomically targeted patient populations, a computational platform is critical to support our translational and clinical research strategy,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Genedata Profiler’s unique approach has the capacity to provide state of the art data integration and analytics. This partnership allows us to leverage Genedata’s expertise to help us bring our drugs to the right patients.”

To support Syros in their translational research strategy and enhance generation of efficacious, targeted treatments, Genedata Profiler equips Syros with the following capabilities:

Related Posts
1 of 38,907
  • Scalable data integration to enable efficient analysis of widely dispersed data of various types
  • Configurable automated workflows to streamline processing, integration, and analysis of a large amount of high-dimensional data
  • Advanced data analytics to help derive novel scientific hypotheses and make highly reliable predictions
  • Efficient, yet secure data sharing tools with fine-grained data access control and role permissions to enable collaboration across and beyond organizational units.

Recommended AI News: West Community Credit Union Chooses Lumin Digital To Provide Enhanced Digital Banking Services

Such integrated, data-driven approach facilitated by Genedata Profiler empowers scientists to decipher subtle trends associated with a specific disease within a cohort of patients, ultimately facilitating patient stratification and optimizing clinical trial design. It also strengthens the ability to unlock novel actionable insights and speed up R&D workflows.

Beyond software, Genedata’s scientific domain expertise, and experience of over 25 years in the biopharma business ensures quick adoption of the platform in the company’s infrastructure, accelerating digital transformation within the translational and clinical research programs.

“We are excited to collaborate with Syros Pharmaceuticals, a leader in the development of small molecules medicines changing the expression of genes, to help bring targeted treatments faster to patients with cancer and monogenic diseases,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata Profiler is perfectly-suited to assist emerging biopharmaceutical companies in their scientific innovation and in their quest for sustainable growth.”

Recommended AI News: Infoworks Replicator Dramatically Accelerates On-Premises Hadoop Data Migration to the Cloud

[To share your insights with us, please write to]

Comments are closed.